Sleep medicine最新文献

{"title":"Effects of one night of sleep deprivation on whole brain intrinsic connectivity distribution using a graph theory neuroimaging approach.","authors":"Rui Zhao, Fu-Min Wang, Chen Cheng, Xue Li, Yin Wang, Fen Zhang, Shan-Gang Li, Yu-Hao Huang, Zi-Yi Zhao, Wei Wei, Xiao-Dan Zhang, Xue-Ping Su, Xue-Juan Yang, Wei Qin, Jin-Bo Sun","doi":"10.1016/j.sleep.2024.11.010","DOIUrl":"https://doi.org/10.1016/j.sleep.2024.11.010","url":null,"abstract":"<p><p>Neuroimaging studies have revealed disturbances in brain functional connectivity (FC) after one night of sleep deprivation (SD). These researches explored the alterations of FC using classical regions of interest (ROI)-based analysis or functional connectivity density. However, these methods need for a priori information about the selected ROIs and a specific correlation threshold to define a connection between two ROIs or voxels, which may bring inconsistent results. In the present study, we adopted a data-driven, whole brain voxel-based graph-theoretical approach, intrinsic connectivity distribution (ICD) analysis, to examine changes of brain connectivity after SD in 52 normal young subjects without any prior knowledge. The cross-hemisphere ICD (ch-ICD) analysis was also performed to discover the effect of SD on cerebral lateralization. We found that sleep-deprived subjects showed significant reduced ICD in default mode network (DMN) and limbic network, and increased ICD in sensorimotor network. Furthermore, after SD, the ICD in the right precuneus showed significant correlation with psychomotor vigilance test (PVT) performance following the stepwise regression analysis after Bonferroni correction (ICD = 0.43 - 0.62∗10 % fast reaction time + 0.31∗the standard deviation of reaction time, p = 0.0012). Follow-up seed-based FC analyses in the right precuneus revealed decreased FC to regions in DMN, visual network, ventral attentional network and frontal-parietal network. Nevertheless, no striking difference of ch-ICD was found following SD. In conclusion, these findings suggested that DMN, especially precuneus may be hubs of FC disturbances associated with vigilance after SD, and may provide new insights into the intervention for SD.</p>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"125 ","pages":"89-99"},"PeriodicalIF":3.8,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of obstructive sleep apnea treatment in reducing fall risk in older adults: Study protocol for a clinical trial","authors":"Kelly Sansom ,&nbsp;Rajani Khanal ,&nbsp;Kimberley S. van Schooten ,&nbsp;Ronaldo D. Piovezan ,&nbsp;David Stevens ,&nbsp;Barbara Toson ,&nbsp;Katherine Bassett ,&nbsp;Lauren Priest ,&nbsp;Stephen R. Lord ,&nbsp;Daina L. Sturnieks ,&nbsp;Chris Barr ,&nbsp;Danny J. Eckert ,&nbsp;Robert Adams ,&nbsp;Sutapa Mukherjee ,&nbsp;Andrew Vakulin","doi":"10.1016/j.sleep.2024.11.003","DOIUrl":"10.1016/j.sleep.2024.11.003","url":null,"abstract":"<div><h3>Background</h3><div>Falls are a major cause of hospitalization fractures and functional decline in older adults. Obstructive sleep apnea (OSA), a highly prevalent sleep breathing disorder in older adults, has emerged as a potentially modifiable risk factor for falls. A small number of uncontrolled studies suggest OSA therapy by continuous positive airway pressure (CPAP) may reduce fall risk. We aim to describe the design of a randomized clinical trial that will evaluate if six months of CPAP intervention can significantly reduce fall risk markers in older adults with OSA.</div></div><div><h3>Methods</h3><div>140 adults aged ≥60 years at risk of falls with diagnosed and untreated OSA will be randomized to receive CPAP and usual care for fall risk or only usual care for fall risk. The primary outcome will be the difference in fall risk scores, derived from the physiological profile assessment, between the two arms six months post-randomization. Secondary outcomes will include differences in gait, quality of life, sleep quality (self-reported and objective home-based monitoring), psychological well-being, cognitive function, physical performance, muscle strength, and body composition at six months post-randomization.</div></div><div><h3>Results</h3><div>Data will be analyzed on an intention-to-treat basis. Ethical approval was obtained from Southern Adelaide Clinical Human Research Ethics Committee in July 2023 (reference: 2023/HRE00081). Outcomes will be disseminated through publication in peer-reviewed journals and presentations at international conferences. Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN) 12623000965606.</div></div><div><h3>Conclusion</h3><div>The findings from this study will provide insight into the causal associations between OSA and fall risk and contribute to high quality evidence required to inform larger clinical trials and future guidelines for fall prevention.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Pages 695-702"},"PeriodicalIF":3.8,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The development and validation of the beliefs about Baby Crying at Night (BBCN) scale","authors":"Marie-Paule Gustin ,&nbsp;Florian Lecuelle ,&nbsp;Royce Anders ,&nbsp;Wendy Leslie ,&nbsp;Patricia Franco ,&nbsp;Benjamin Putois","doi":"10.1016/j.sleep.2024.10.032","DOIUrl":"10.1016/j.sleep.2024.10.032","url":null,"abstract":"<div><h3>Objective</h3><div>What are young children trying to express when they cry at night? According to Sadeh, parental beliefs about why their child is crying may play a role in the development and persistence of their child's insomnia. The aim of this study was to create a scale that specifically assesses these parental interpretations in different dimensions.</div></div><div><h3>Methods</h3><div>Children aged between 6 months and 3 years with either good sleep habits or behavioural insomnia were recruited. An initial, 20-item scale for the beliefs of why one's baby is crying at night was developed, with all items on a 7-point Likert span. The results of this scale from a large sample were then submitted to Exploratory (EFA) and confirmatory (CFA) factor analyses to converge on a final version and evaluate its psychometric properties and validity.</div></div><div><h3>Results</h3><div>Among the 1009 subjects included in the analyses (46.2 % female, mean age: 1.63 ± 0.73, good sleepers n = 425 and bad sleepers n = 584). After the factor analysis was performed, a 14-item scale with 4 subscales quantifying each interpretation type resulted: namely, “Need for attachment” (5 items), “Need to cry before falling asleep” (3 items), “Leaving a child to cry during the night is traumatizing for the child” (4 items) and “Is in pain” (2 items). The CFA further confirmed an appropriate fit. The most divergent subscale between groups was the “Need for attachment” subscale.</div></div><div><h3>Conclusion</h3><div>This study proposes the first scale known to focus exclusively on parent interpretations of their child's night-time crying, without taking into account their nursing behaviours. It provides a clinical tool for more effectively discussing with parents, in order to address potential dysfunctional beliefs in the context of early childhood insomnia complaints, as well as a research tool for considering cognitive dimensions in the aetiology and treatment of behavioural insomnia.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Pages 745-753"},"PeriodicalIF":3.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the intersection of video gaming, sleep, and mental health in modern adults","authors":"Guilherme Nobre Nogueira","doi":"10.1016/j.sleep.2024.10.028","DOIUrl":"10.1016/j.sleep.2024.10.028","url":null,"abstract":"","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Page 649"},"PeriodicalIF":3.8,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy","authors":"Ramakrishna Nirogi ,&nbsp;Anil Shinde ,&nbsp;Vinod Kumar Goyal ,&nbsp;Jyothsna Ravula ,&nbsp;Vijay Benade ,&nbsp;Satish Jetta ,&nbsp;Santosh Kumar Pandey ,&nbsp;Ramkumar Subramanian ,&nbsp;Veera Raghava Chowdary Palacharla ,&nbsp;Abdul Rasheed Mohammed ,&nbsp;Renny Abraham ,&nbsp;Dhanunjay Kumar Dogiparti ,&nbsp;Ilayaraja Kalaikadhiban ,&nbsp;Pradeep Jayarajan ,&nbsp;Venkat Jasti ,&nbsp;Richard K. Bogan","doi":"10.1016/j.sleep.2024.10.037","DOIUrl":"10.1016/j.sleep.2024.10.037","url":null,"abstract":"<div><div>Narcolepsy is a rare, chronic neurological disorder characterized by a dysregulated sleep-wake cycle, with core clinical features including excessive daytime sleepiness (EDS), cataplexy, hypnopompic/hypnagogic hallucinations, and sleep paralysis. Several treatment options are available for the symptomatic management of narcolepsy, but they have limitations. Comorbidities of narcolepsy further limit the treatment choices. Blocking of histamine 3 (H3) receptors has been demonstrated to be a viable approach for the management of symptoms of narcolepsy. Samelisant (SUVN-G3031) is a new H3 receptor inverse agonist. The efficacy, safety, tolerability, and pharmacokinetics of Samelisant in narcolepsy patients were evaluated in a phase 2, double-blind, placebo-controlled study (<span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> identifier: NCT04072380). Patients diagnosed with narcolepsy according to the International Classification of Sleep Disorders criteria and having an Epworth Sleepiness Scale (ESS) score of ≥12 and a mean Maintenance of Wakefulness Test (MWT) time of &lt;12 min across the 4 sessions at baseline were enrolled. The total study duration was up to 7 weeks, which included a screening period of 4 weeks, a treatment period of 2 weeks, and a safety follow-up 1 week after the last study drug administration. The primary efficacy measure was the change in total ESS score compared to placebo. Secondary and exploratory assessments included the Clinical Global Impression of Severity, MWT, Clinical Global Impression of Change, Patient Global Impression of Change and cataplexy rate. Safety assessments included monitoring adverse events (AEs) and laboratory assessments. Of the 426 patients screened, 190 were randomized. The safety and intention-to-treat population included 188 and 164 patients, respectively. A statistically significant treatment effect of Samelisant was observed on the primary endpoint, indicating improvements in EDS. The treatment's impact on EDS was also evident on the other patients' and clinicians' perspectives scales. The AEs reported in ≥5 % patients in any treatment groups were insomnia, abnormal dreams, nausea, and hot flush. Global phase 3 studies and long-term safety and efficacy assessments of Samelisant are planned to reaffirm the current findings.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Pages 618-626"},"PeriodicalIF":3.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of sleep restriction on biomarkers of thyroid function: Two pooled randomized trials","authors":"Megan E. Petrov ,&nbsp;Faris M. Zuraikat ,&nbsp;Bin Cheng ,&nbsp;Brooke Aggarwal ,&nbsp;Sanja Jelic ,&nbsp;Blandine Laferrère ,&nbsp;Marie-Pierre St-Onge","doi":"10.1016/j.sleep.2024.10.035","DOIUrl":"10.1016/j.sleep.2024.10.035","url":null,"abstract":"<div><h3>Background</h3><div>Chronic, mildly insufficient sleep is associated with increased cardiometabolic risk, but whether the regulation of thyroid hormones and related growth factors are mechanisms of this association is unclear. We investigated whether 6 wk of mild sleep restriction (SR) alters levels of free thyroxine (FT4), thyroid stimulating hormone (TSH), and fibroblast growth factor-21 (FGF-21), a modulator of FT4, in adults with adequate habitual sleep (AS; 7–9 h/night).</div></div><div><h3>Methods</h3><div>Healthy adults participated in one of two randomized, crossover studies with identical 6-wk intervention phases: AS and SR (1.5 h/night &lt; AS). Fasted blood samples were collected at baseline and endpoint of each phase. Outcomes were concentrations of FT4, TSH, and FGF-21 (women only). Linear mixed models tested the effects of SR vs AS on the outcomes, adjusting for baseline levels, week, sex, and sex-by-condition interaction.</div></div><div><h3>Results</h3><div>Thirty participants (20 women; 73% racial/ethnic minority; age 21–64 y [<em>M</em>±<em>SD</em> = 36.2 ± 12.8 y]) were included. In the full sample, no effects of SR on FT4 (β±SE = 0.02 ± 0.04, <em>p</em> = 0.654) or TSH (β±SE = −0.02 ± 0.04, <em>p</em> = 0.650) were observed; however, there were sex-by-condition interactions for both FT4 (<em>p-interaction</em> = 0.056) and TSH (<em>p-interaction</em> = 0.049). In sex-stratified analyses, TSH was reduced in SR vs. AS in women (β±SE = −0.11 ± 0.04, p = 0.011, Cohen's <em>f</em>² = 0.55) but not men (β±SE = 0.09 ± 0.08, p = 0.261). Among women (n = 17), FGF-21 was not significantly different between conditions (β±SE = 8.51 ± 17.70, <em>p</em> = 0.638).</div></div><div><h3>Conclusion</h3><div>Prolonged mild SR reduces TSH in women, whereas FT4 and FGF-21 remain unaffected compared with AS. If sustained, disruptions to the thyrotropic axis in women may contribute to their more pronounced cardiometabolic risk in response to SR compared with men.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Pages 606-612"},"PeriodicalIF":3.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep disorders in cerebrotendinous xanthomatosis: A case series","authors":"Liandra Rayanne de Sousa Barbosa ,&nbsp;Antônio Edvan Camelo-Filho ,&nbsp;Pedro Lucas Grangeiro de Sá Barreto Lima ,&nbsp;Alissa Elen Formiga Moura ,&nbsp;Andre Luis Santos Pessoa ,&nbsp;Pedro Braga-Neto ,&nbsp;Manoel Alves Sobreira-Neto ,&nbsp;Paulo Ribeiro Nóbrega","doi":"10.1016/j.sleep.2024.10.034","DOIUrl":"10.1016/j.sleep.2024.10.034","url":null,"abstract":"<div><div>Cerebrotendinous xanthomatosis (CTX) is a rare genetic disorder characterized by a variety of neurological and systemic symptoms, including cerebellar ataxia, cataracts, tendon xanthomas, and polyneuropathy. This study aimed to investigate sleep patterns and disorders in four patients diagnosed with cerebrotendinous xanthomatosis. All participants reported significant sleep disturbances, and objective assessments confirmed the presence of insomnia, excessive daytime sleepiness, obstructive sleep apnea, and periodic limb movements. Notably, this is the first study to incorporate sleep assessments into the clinical management of CTX patients, which may be crucial for improving their quality of life. Further research is warranted to deepen our understanding of the potential impact of cholestanol deposits on regions of the central nervous system involved in sleep and circadian rhythm regulation.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Pages 613-617"},"PeriodicalIF":3.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A mendelian randomization study investigating the association between sleep apnea risk and cheese consumption through biomarker analysis","authors":"Yanjiang Yang ,&nbsp;Xiaorui Wang ,&nbsp;Wenwen Yang","doi":"10.1016/j.sleep.2024.10.029","DOIUrl":"10.1016/j.sleep.2024.10.029","url":null,"abstract":"<div><div>Cheese consumption may play a role in mitigating sleep apnea risk, according to our Mendelian randomization (MR) study. Sleep apnea, a prevalent disorder associated with various health complications, affects millions worldwide, generating interest in dietary interventions. This study analyzed data from the UK Biobank and the FinnGen Biobank, focusing on cheese intake and its potential impact on sleep apnea through various biomarkers. Results revealed a significant inverse association between cheese consumption and sleep apnea risk (OR=0.724, p=0.00478), indicating that higher cheese intake is linked to a reduced likelihood of developing the disorder. Additionally, the analysis identified six biomarkers, including aspartate aminotransferase (1.33 %), urea (3.85 %), cystatin C (2.98 %), sex hormone-binding globulin (1.78 %), testosterone (1.94 %), and diastolic blood pressure (5.46 %), as mediators of this relationship. Notably, cheese consumption influenced levels of 23 biomarkers. These findings underscore the potential of dietary interventions in public health strategies aimed at decreasing sleep apnea prevalence and associated health risks. Overall, this study highlights the complex connections between diet, biomarkers, and sleep apnea, emphasizing the necessity for further research across diverse populations to enhance the generalizability of these results.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Pages 737-744"},"PeriodicalIF":3.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The trajectories and associations of sleep disturbance symptoms with suicidal ideation in adolescents: A three-wave longitudinal study","authors":"Xiangting Zhang,&nbsp;Yifan Zhang,&nbsp;Luowei Bu,&nbsp;Huolian Li,&nbsp;Haoxian Ye,&nbsp;Dongfang Wang,&nbsp;Fang Fan","doi":"10.1016/j.sleep.2024.10.031","DOIUrl":"10.1016/j.sleep.2024.10.031","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to investigate the developmental trajectories of sleep disturbance symptoms and examine whether specific trajectory memberships of sleep disturbance symptoms could prospectively predict suicidal ideation (SI) among a large sample of Chinese adolescents over one year.</div></div><div><h3>Methods</h3><div>A three-wave longitudinal study was conducted from April 2021 to June 2022, with a sample of 19,095 adolescents from Shenzhen in Guangdong Province, China (51.2 % males; mean age = 12.4 ± 1.6 years at baseline). Socio-demographics (at baseline), SI, sleep disturbance symptoms (at each assessment), depressive symptoms (at the last follow-up), and negative life events (at two follow-ups) were assessed. Data were analyzed employing Growth Mixture Modeling and binary logistic regressions.</div></div><div><h3>Results</h3><div>The Growth Mixture Modeling identified four trajectories of sleep disturbance symptoms over one year: resistant group (76.2 %), delayed-dysfunction group (8.8 %), recovery group (7.4 %), and chronic-dysfunction group (7.6 %). Binary logistic regression analysis revealed that adolescents in the group of delayed-dysfunction (OR = 2.86, 95 % CI = 2.51–3.27) and chronic-dysfunction (OR = 2.14, 95 % CI = 1.84–2.47) exhibited higher risks of developing SI compared to those in the resistant group, even after controlling for socio-demographics, negative life events, depressive symptoms, and baseline SI.</div></div><div><h3>Conclusions</h3><div>These findings underscore the importance of identifying individuals at higher risks of sleep disturbance and providing personalized and effective mental health services to reduce the incidence of SI.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Pages 591-597"},"PeriodicalIF":3.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing sleep and mood in depressed adolescents: A randomized trial on nurse-led digital cognitive behavioral therapy for insomnia","authors":"Nan Bai ,&nbsp;Min Yin","doi":"10.1016/j.sleep.2024.10.030","DOIUrl":"10.1016/j.sleep.2024.10.030","url":null,"abstract":"<div><h3>Background</h3><div>Despite the effectiveness of digital cognitive behavior therapy for insomnia (dCBT-I) in treating comorbid insomnia and depression, its accessibility and high dropout rates among adolescents and young adults remain significant limitations. A potential solution could be nurse-led dCBT-I. This study evaluates the feasibility and efficacy of nurse-led dCBT-I in reducing insomnia symptoms and improving mood in adolescents and young adults with depression.</div></div><div><h3>Aims</h3><div>Our objective was to evaluate the feasibility and effectiveness of a nurse-led dCBT-I in reducing insomnia severity among adolescents and young adults with depression.</div></div><div><h3>Methods</h3><div>A parallel-group randomized controlled trial involved 40 adolescents and young adults aged 14 to 24 with major depressive disorder and insomnia. They were assigned to receive either a nurse-led 6-week dCBT-I or usual care. The study evaluated outcomes such as insomnia severity, depression severity, and sleep parameters. Measurements were taken at baseline, immediately after the intervention (6 weeks), and during a follow-up at 18 weeks.</div></div><div><h3>Results</h3><div>The intention-to-treat analysis was performed using a generalized linear mixed model (GLMM). Results indicated that, compared to the control group, participants in the intervention group exhibited a significant reduction in insomnia severity at the 18-week follow-up, with a large effect size (Cohen's d = −0.965, p &lt; 0.001). Additionally, the intervention group demonstrated a significant decrease in depression severity both at the end of the intervention (Cohen's d = −0.686, p = 0.001) and at the 18-week follow-up (Cohen's d = −0.508, p = 0.011), indicating a medium effect size.</div></div><div><h3>Conclusions</h3><div>Nurse-led dCBT-I is an effective treatment for adolescents and young adults with depression and insomnia.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Pages 627-636"},"PeriodicalIF":3.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}